Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-04-20 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, their identification, and remediation status. The document includes detailed internal control standards, scope, and conclusions about the effectiveness of internal controls. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The content aligns with an Audit Report / Information filing, which covers audit results and applied accounting principles but is distinct from the full Annual Report (10-K). The document length is 4026 characters, which is sufficient for a detailed report but not a brief announcement. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2022
2023-04-20 Chinese
金宇生物技术股份有限公司第十一届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the review and approval of various reports and proposals, including the 2022 Annual Report, 2023 Q1 Report, profit distribution plan, internal control evaluation report, and accounting policy changes. The document states that the full reports are disclosed on the Shanghai Stock Exchange website and does not contain the full financial statements or detailed financial data itself. The document is relatively short (2325 characters) and serves as an announcement of the Supervisory Board's meeting decisions and approvals rather than the reports themselves. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and meeting resolution notice rather than the full Annual Report (10-K) or Interim Report (IR).
2023-04-20 Chinese
金宇生物技术股份有限公司关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 金宇生物技术股份有限公司 regarding the use of idle self-owned funds for cash management. It details the investment scope, amount, duration, risk control measures, and independent director opinions. The document is an announcement of a corporate financing or capital management activity, specifically about cash management and investment of idle funds, but it does not contain financial statements or detailed financial results. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or legal proceeding. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities related to cash management and investment of funds.
2023-04-20 Chinese
金宇生物技术股份有限公司关于股份回购实施结果暨股份变动公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement about the company's share repurchase (buyback) implementation results and related shareholding changes. It includes specifics on the number of shares repurchased, prices, total funds used, approvals, and subsequent handling of the repurchased shares. It also reports on insider transactions during the repurchase period. The document is not a financial report, earnings release, or management discussion, but rather a formal disclosure of the share buyback completion and shareholding changes. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length is about 3060 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the correct classification is POS with high confidence.
2023-04-03 Chinese
金宇生物技术股份有限公司关于签订非洲猪瘟亚单位（纳米颗粒）疫苗技术开发（合作）合同的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 金宇生物技术股份有限公司 regarding the signing of a technology development cooperation contract for an African swine fever subunit (nanoparticle) vaccine. It details the parties involved, the nature of the cooperation, the project's background, and risk warnings. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about a contract signing and research collaboration, not a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a Board/Management change, nor a voting result or capital change. The document is a regulatory announcement about a material contract and cooperation, which fits best under Regulatory Filings (RNS). The document length is about 3000 characters, and it is a full announcement, not a brief report publication notice. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-03-20 Chinese
经世律师事务所关于金宇生物技术股份有限公司2023年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of a company's 2023 second extraordinary general meeting of shareholders. It details the legality and validity of the meeting's call, attendance, and voting on various proposals, including non-public issuance of A shares and employee stock ownership plans. The document includes detailed voting results and confirms compliance with relevant laws and company articles. This is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or a simple announcement but a legal opinion on the shareholder meeting and its voting results. The content aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting outcomes from a shareholder meeting.
2023-03-16 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.